Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Неинвазивные и лабораторные методы диагностики алкогольной болезни печени: литературный обзор
Неинвазивные и лабораторные методы диагностики алкогольной болезни печени: литературный обзор
Кузма Фади, Павлов Ч.С., Усанова А.А. и др. Неинвазивные и лабораторные методы диагностики алкогольной болезни печени: литературный обзор. Consilium Medicum. 2017; 19 (8.2. Гастроэнтерология): 27–32. DOI: 10.26442/2075-1753_19.8.2.27-32
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье представлен обзор публикаций по диагностике алкогольной болезни печени, в частности неинвазивных методов как важного компонента диагностического поиска данного заболевания.
Ключевые слова: неинвазивные методы, сывороточные маркеры, алкогольная болезнь печени, фибротест, Фибромете, эштест.
Key words: noninvasive methods, serum markers, alcoholic liver disease, fibrotest, Fibrometer, ashtest.
Ключевые слова: неинвазивные методы, сывороточные маркеры, алкогольная болезнь печени, фибротест, Фибромете, эштест.
________________________________________________
Key words: noninvasive methods, serum markers, alcoholic liver disease, fibrotest, Fibrometer, ashtest.
Полный текст
Список литературы
1. Маев И.В., Абдурахманов Д.Т., Дичева Д.Т. и др. Алкогольная болезнь печени. Клин. гепатология. 2012; 8 (2): 33–40. / Maev I.V., Abdurakhmanov D.T., Dicheva D.T. i dr. Alkogol'naia bolezn' pecheni. Klin. gepatologiia. 2012; 8 (2): 33–40. [in Russian]
2. Hüllinghorst R, Kaldeweil D, Lindemann F. Geeshacht: Neuland Verlagsgesellschaft mbH. Jahrbuch Sucht 2007. ISBN-10: 3875812700; ISBN-13: 987-3875812701.
3. Park SH, Kim CH, Kim DJ et al. Prevalence of alcoholic liver disease among Korean adults: results from the fourth Korea National Health and Nutrition Examination Survey, 2009. Subst Use Misuse 2011; 46: 1755–62.
4. Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res 2010; 34: 955–67.
5. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399–420.
6. Хомерики С.Г., Хомерики Н.М. Алкогольная болезнь печени: механизмы развития, морфологические проявления, дифференциальная диагностика и патогенетические подходы к терапии. Гастроэнтерология (Прил. к журн. Consilium Medicum). 2012; 1: 27–34. / Khomeriki S.G., Khomeriki N.M. Alkogol'naia bolezn' pecheni: mekhanizmy razvitiia, morfologicheskie proiavleniia, differentsial'naia diagnostika i patogeneticheskie podkhody k terapii. Gastroenterology (Suppl. Consilium Medicum). 2012; 14 (1): 27–34. [in Russian]
7. Павлов Ч.С., Глушенков Д.В., Ивашкин В.Т. Современные возможности эластометрии, фибро- и актитеста в диагностике фиброза печени. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2008; 18 (4): 43–52. / Pavlov Ch.S., Glushen-kov D.V., Ivashkin V.T. Sovremennye vozmozhnosti elastometrii, fibro- i aktitesta v diagnostike fibroza pecheni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2008; 18 (4): 43–52. [in Russian]
8. Павлов Ч.С., Ивашкин В.Т., Шульпекова Ю.О., Золотаревский В.Б. Современные представления о патогенезе, диагностике и лечении фиброза печени. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2005; 15 (2): 13–20. / Pavlov Ch.S., Ivashkin V.T., Shulpekova Yu.O., Zolotarevskii V.B. Sovremennye predstavleniia o patogeneze, diagnostike i lechenii fibroza pecheni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2005; 15 (2): 13–20. [in Russian]
9. Павлов Ч.С., Золоторевский В.Б., Ивашкин В.Т. и др. Современные методы ранней диагностики фиброза печени. Клин. медицина. 2005; 83 (12): 58–60. / Pavlov Ch.S., Zolotorevskii V.B., Ivashkin V.T. i dr. Sovremennye metody rannei diagnostiki fibroza pecheni. Klin. meditsina. 2005; 83 (12): 58–60. [in Russian]
10. Павлов Ч.С., Ивашкин В.Т. Биопсия печени: методология и практика сегодня. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2006; 16 (4): 65–78. / Pavlov Ch.S., Ivashkin V.T. Biopsiia pecheni: metodologiia i praktika segodnia. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2006; 16 (4): 65–78. [in Russian]
11. Павлов Ч.С. Принципы диагностики и подходы к терапии фиброза и цирроза печени. РМЖ. 2007; 1: 11. / Pavlov Ch.S. Printsipy diagnostiki i podkhody k terapii fibroza i tsirroza pecheni. RMZh. 2007; 1: 11. [in Russian]
12. Mueller S. Noninvasive assessment of patients with alcoholic liver disease. Clin Liver Dis 2013; 2: 68–71.
13. Mukai M, Ozasa K, Hayashi K, Kawai K. Various S-GOT/S-GPT ratios in nonviral liver disorders and related physical conditions and life-style. Dig Dis Sci 2002; 47: 549–55.
14. Вельков В.В. Сывороточные биомаркеры фиброза печени: до свидания, биопсия? М.: Lomonosoff Print, 2009. / Velkov V.V. Syvorotochnye biomarkery fibroza pecheni: do svidaniia, biopsiia? M.: Lomonosoff Print, 2009. [in Russian]
15. Witters P, Freson K, Verslype CP et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment. Pharmacol Ther 2008; 27: 1017–29.
16. Parés A, Deulofeu R, Giménez A et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24: 1399–403.
17. Naveau S, Gaudé G, Asnacios A et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97–105.
18. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069–75.
19. Naveau S, Raynard B, Ratziu V et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3: 167–4.
20. Parkes J, Roderick P, Harris S et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245–51.
21. EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. J Hepatol 2012; 57: 399–420.
22. Ophir J. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrasonic Imaging 1991; 13: 111D34.
23. Зыкин Б.И., Постнова Н.А., Медведев М.Е. Ультразвуковая эластография. Мед. алфавит. 2013; 10: 14–9. / Zykin B.I., Postnova N.A., Medvedev M.E. Ul'trazvukovaia elastografiia. Med. alfavit. 2013; 10: 14–9. [in Russian]
24. Осипов Л.В. Технологии эластографии в ультразвуковой диагностике. Мед. алфавит. 2013; 3–4: 5–21. / Osipov L.V. Tekhnologii elastografii v ul'trazvukovoi diagnostike. Med. alfavit. 2013; 3–4: 5–21. [in Russian]
25. Cournane S, Fagan AJ, Browne JE. Review of Ultrasound Elastography Quality Control and Training Test Phantoms. Ultrasound 2012; 20: 16–23.
26. Pavlov CS, Casazza G, Nikolova D et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev 2015; 1: CD010542.
27. Nahon P, Kettaneh A, Tengher-Barna I et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49: 1062–8.
28. Lemoine M, Katsahian S, Ziol M et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther 2008; 28: 1102–10.
2. Hüllinghorst R, Kaldeweil D, Lindemann F. Geeshacht: Neuland Verlagsgesellschaft mbH. Jahrbuch Sucht 2007. ISBN-10: 3875812700; ISBN-13: 987-3875812701.
3. Park SH, Kim CH, Kim DJ et al. Prevalence of alcoholic liver disease among Korean adults: results from the fourth Korea National Health and Nutrition Examination Survey, 2009. Subst Use Misuse 2011; 46: 1755–62.
4. Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res 2010; 34: 955–67.
5. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399–420.
6. Khomeriki S.G., Khomeriki N.M. Alkogol'naia bolezn' pecheni: mekhanizmy razvitiia, morfologicheskie proiavleniia, differentsial'naia diagnostika i patogeneticheskie podkhody k terapii. Gastroenterology (Suppl. Consilium Medicum). 2012; 14 (1): 27–34. [in Russian]
7. Pavlov Ch.S., Glushen-kov D.V., Ivashkin V.T. Sovremennye vozmozhnosti elastometrii, fibro- i aktitesta v diagnostike fibroza pecheni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2008; 18 (4): 43–52. [in Russian]
8. Pavlov Ch.S., Ivashkin V.T., Shulpekova Yu.O., Zolotarevskii V.B. Sovremennye predstavleniia o patogeneze, diagnostike i lechenii fibroza pecheni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2005; 15 (2): 13–20. [in Russian]
9. Pavlov Ch.S., Zolotorevskii V.B., Ivashkin V.T. i dr. Sovremennye metody rannei diagnostiki fibroza pecheni. Klin. meditsina. 2005; 83 (12): 58–60. [in Russian]
10. Pavlov Ch.S., Ivashkin V.T. Biopsiia pecheni: metodologiia i praktika segodnia. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2006; 16 (4): 65–78. [in Russian]
11. Pavlov Ch.S. Printsipy diagnostiki i podkhody k terapii fibroza i tsirroza pecheni. RMZh. 2007; 1: 11. [in Russian]
12. Mueller S. Noninvasive assessment of patients with alcoholic liver disease. Clin Liver Dis 2013; 2: 68–71.
13. Mukai M, Ozasa K, Hayashi K, Kawai K. Various S-GOT/S-GPT ratios in nonviral liver disorders and related physical conditions and life-style. Dig Dis Sci 2002; 47: 549–55.
14. Velkov V.V. Syvorotochnye biomarkery fibroza pecheni: do svidaniia, biopsiia? M.: Lomonosoff Print, 2009. [in Russian]
15. Witters P, Freson K, Verslype CP et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment. Pharmacol Ther 2008; 27: 1017–29.
16. Parés A, Deulofeu R, Giménez A et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24: 1399–403.
17. Naveau S, Gaudé G, Asnacios A et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97–105.
18. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069–75.
19. Naveau S, Raynard B, Ratziu V et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3: 167–4.
20. Parkes J, Roderick P, Harris S et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245–51.
21. EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. J Hepatol 2012; 57: 399–420.
22. Ophir J. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrasonic Imaging 1991; 13: 111D34.
23. Zykin B.I., Postnova N.A., Medvedev M.E. Ul'trazvukovaia elastografiia. Med. alfavit. 2013; 10: 14–9. [in Russian]
24. Osipov L.V. Tekhnologii elastografii v ul'trazvukovoi diagnostike. Med. alfavit. 2013; 3–4: 5–21. [in Russian]
25. Cournane S, Fagan AJ, Browne JE. Review of Ultrasound Elastography Quality Control and Training Test Phantoms. Ultrasound 2012; 20: 16–23.
26. Pavlov CS, Casazza G, Nikolova D et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev 2015; 1: CD010542.
27. Nahon P, Kettaneh A, Tengher-Barna I et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49: 1062–8.
28. Lemoine M, Katsahian S, Ziol M et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther 2008; 28: 1102–10.
2. Hüllinghorst R, Kaldeweil D, Lindemann F. Geeshacht: Neuland Verlagsgesellschaft mbH. Jahrbuch Sucht 2007. ISBN-10: 3875812700; ISBN-13: 987-3875812701.
3. Park SH, Kim CH, Kim DJ et al. Prevalence of alcoholic liver disease among Korean adults: results from the fourth Korea National Health and Nutrition Examination Survey, 2009. Subst Use Misuse 2011; 46: 1755–62.
4. Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res 2010; 34: 955–67.
5. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399–420.
6. Хомерики С.Г., Хомерики Н.М. Алкогольная болезнь печени: механизмы развития, морфологические проявления, дифференциальная диагностика и патогенетические подходы к терапии. Гастроэнтерология (Прил. к журн. Consilium Medicum). 2012; 1: 27–34. / Khomeriki S.G., Khomeriki N.M. Alkogol'naia bolezn' pecheni: mekhanizmy razvitiia, morfologicheskie proiavleniia, differentsial'naia diagnostika i patogeneticheskie podkhody k terapii. Gastroenterology (Suppl. Consilium Medicum). 2012; 14 (1): 27–34. [in Russian]
7. Павлов Ч.С., Глушенков Д.В., Ивашкин В.Т. Современные возможности эластометрии, фибро- и актитеста в диагностике фиброза печени. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2008; 18 (4): 43–52. / Pavlov Ch.S., Glushen-kov D.V., Ivashkin V.T. Sovremennye vozmozhnosti elastometrii, fibro- i aktitesta v diagnostike fibroza pecheni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2008; 18 (4): 43–52. [in Russian]
8. Павлов Ч.С., Ивашкин В.Т., Шульпекова Ю.О., Золотаревский В.Б. Современные представления о патогенезе, диагностике и лечении фиброза печени. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2005; 15 (2): 13–20. / Pavlov Ch.S., Ivashkin V.T., Shulpekova Yu.O., Zolotarevskii V.B. Sovremennye predstavleniia o patogeneze, diagnostike i lechenii fibroza pecheni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2005; 15 (2): 13–20. [in Russian]
9. Павлов Ч.С., Золоторевский В.Б., Ивашкин В.Т. и др. Современные методы ранней диагностики фиброза печени. Клин. медицина. 2005; 83 (12): 58–60. / Pavlov Ch.S., Zolotorevskii V.B., Ivashkin V.T. i dr. Sovremennye metody rannei diagnostiki fibroza pecheni. Klin. meditsina. 2005; 83 (12): 58–60. [in Russian]
10. Павлов Ч.С., Ивашкин В.Т. Биопсия печени: методология и практика сегодня. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2006; 16 (4): 65–78. / Pavlov Ch.S., Ivashkin V.T. Biopsiia pecheni: metodologiia i praktika segodnia. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2006; 16 (4): 65–78. [in Russian]
11. Павлов Ч.С. Принципы диагностики и подходы к терапии фиброза и цирроза печени. РМЖ. 2007; 1: 11. / Pavlov Ch.S. Printsipy diagnostiki i podkhody k terapii fibroza i tsirroza pecheni. RMZh. 2007; 1: 11. [in Russian]
12. Mueller S. Noninvasive assessment of patients with alcoholic liver disease. Clin Liver Dis 2013; 2: 68–71.
13. Mukai M, Ozasa K, Hayashi K, Kawai K. Various S-GOT/S-GPT ratios in nonviral liver disorders and related physical conditions and life-style. Dig Dis Sci 2002; 47: 549–55.
14. Вельков В.В. Сывороточные биомаркеры фиброза печени: до свидания, биопсия? М.: Lomonosoff Print, 2009. / Velkov V.V. Syvorotochnye biomarkery fibroza pecheni: do svidaniia, biopsiia? M.: Lomonosoff Print, 2009. [in Russian]
15. Witters P, Freson K, Verslype CP et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment. Pharmacol Ther 2008; 27: 1017–29.
16. Parés A, Deulofeu R, Giménez A et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24: 1399–403.
17. Naveau S, Gaudé G, Asnacios A et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97–105.
18. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069–75.
19. Naveau S, Raynard B, Ratziu V et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3: 167–4.
20. Parkes J, Roderick P, Harris S et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245–51.
21. EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. J Hepatol 2012; 57: 399–420.
22. Ophir J. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrasonic Imaging 1991; 13: 111D34.
23. Зыкин Б.И., Постнова Н.А., Медведев М.Е. Ультразвуковая эластография. Мед. алфавит. 2013; 10: 14–9. / Zykin B.I., Postnova N.A., Medvedev M.E. Ul'trazvukovaia elastografiia. Med. alfavit. 2013; 10: 14–9. [in Russian]
24. Осипов Л.В. Технологии эластографии в ультразвуковой диагностике. Мед. алфавит. 2013; 3–4: 5–21. / Osipov L.V. Tekhnologii elastografii v ul'trazvukovoi diagnostike. Med. alfavit. 2013; 3–4: 5–21. [in Russian]
25. Cournane S, Fagan AJ, Browne JE. Review of Ultrasound Elastography Quality Control and Training Test Phantoms. Ultrasound 2012; 20: 16–23.
26. Pavlov CS, Casazza G, Nikolova D et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev 2015; 1: CD010542.
27. Nahon P, Kettaneh A, Tengher-Barna I et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49: 1062–8.
28. Lemoine M, Katsahian S, Ziol M et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther 2008; 28: 1102–10.
________________________________________________
2. Hüllinghorst R, Kaldeweil D, Lindemann F. Geeshacht: Neuland Verlagsgesellschaft mbH. Jahrbuch Sucht 2007. ISBN-10: 3875812700; ISBN-13: 987-3875812701.
3. Park SH, Kim CH, Kim DJ et al. Prevalence of alcoholic liver disease among Korean adults: results from the fourth Korea National Health and Nutrition Examination Survey, 2009. Subst Use Misuse 2011; 46: 1755–62.
4. Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res 2010; 34: 955–67.
5. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399–420.
6. Khomeriki S.G., Khomeriki N.M. Alkogol'naia bolezn' pecheni: mekhanizmy razvitiia, morfologicheskie proiavleniia, differentsial'naia diagnostika i patogeneticheskie podkhody k terapii. Gastroenterology (Suppl. Consilium Medicum). 2012; 14 (1): 27–34. [in Russian]
7. Pavlov Ch.S., Glushen-kov D.V., Ivashkin V.T. Sovremennye vozmozhnosti elastometrii, fibro- i aktitesta v diagnostike fibroza pecheni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2008; 18 (4): 43–52. [in Russian]
8. Pavlov Ch.S., Ivashkin V.T., Shulpekova Yu.O., Zolotarevskii V.B. Sovremennye predstavleniia o patogeneze, diagnostike i lechenii fibroza pecheni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2005; 15 (2): 13–20. [in Russian]
9. Pavlov Ch.S., Zolotorevskii V.B., Ivashkin V.T. i dr. Sovremennye metody rannei diagnostiki fibroza pecheni. Klin. meditsina. 2005; 83 (12): 58–60. [in Russian]
10. Pavlov Ch.S., Ivashkin V.T. Biopsiia pecheni: metodologiia i praktika segodnia. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2006; 16 (4): 65–78. [in Russian]
11. Pavlov Ch.S. Printsipy diagnostiki i podkhody k terapii fibroza i tsirroza pecheni. RMZh. 2007; 1: 11. [in Russian]
12. Mueller S. Noninvasive assessment of patients with alcoholic liver disease. Clin Liver Dis 2013; 2: 68–71.
13. Mukai M, Ozasa K, Hayashi K, Kawai K. Various S-GOT/S-GPT ratios in nonviral liver disorders and related physical conditions and life-style. Dig Dis Sci 2002; 47: 549–55.
14. Velkov V.V. Syvorotochnye biomarkery fibroza pecheni: do svidaniia, biopsiia? M.: Lomonosoff Print, 2009. [in Russian]
15. Witters P, Freson K, Verslype CP et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment. Pharmacol Ther 2008; 27: 1017–29.
16. Parés A, Deulofeu R, Giménez A et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24: 1399–403.
17. Naveau S, Gaudé G, Asnacios A et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97–105.
18. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069–75.
19. Naveau S, Raynard B, Ratziu V et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3: 167–4.
20. Parkes J, Roderick P, Harris S et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245–51.
21. EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. J Hepatol 2012; 57: 399–420.
22. Ophir J. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrasonic Imaging 1991; 13: 111D34.
23. Zykin B.I., Postnova N.A., Medvedev M.E. Ul'trazvukovaia elastografiia. Med. alfavit. 2013; 10: 14–9. [in Russian]
24. Osipov L.V. Tekhnologii elastografii v ul'trazvukovoi diagnostike. Med. alfavit. 2013; 3–4: 5–21. [in Russian]
25. Cournane S, Fagan AJ, Browne JE. Review of Ultrasound Elastography Quality Control and Training Test Phantoms. Ultrasound 2012; 20: 16–23.
26. Pavlov CS, Casazza G, Nikolova D et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev 2015; 1: CD010542.
27. Nahon P, Kettaneh A, Tengher-Barna I et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49: 1062–8.
28. Lemoine M, Katsahian S, Ziol M et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther 2008; 28: 1102–10.
Авторы
Кузма Фади1*, Ч.С.Павлов2, А.А.Усанова1, Д.В.Глушенков2, Е.А.Кузнецова2, М.Ч.Семенистая2
1 ФГБОУ ВО «Национальный исследовательский Мордовский государственный университет им. Н.П.Огарева». 430005, Россия, Саранск, ул. Большевистская, д. 68;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*fadykuzma@mail.ru
1 N.P.Ogarev National Research Mordovia State University. 430005, Russian Federation, Saransk, ul. Bol'shevistskaia, d. 68;
2 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*fadykuzma@mail.ru
1 ФГБОУ ВО «Национальный исследовательский Мордовский государственный университет им. Н.П.Огарева». 430005, Россия, Саранск, ул. Большевистская, д. 68;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*fadykuzma@mail.ru
________________________________________________
1 N.P.Ogarev National Research Mordovia State University. 430005, Russian Federation, Saransk, ul. Bol'shevistskaia, d. 68;
2 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*fadykuzma@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.